Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001214346 | SCV001386023 | pathogenic | not provided | 2023-12-18 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Ile431Argfs*16) in the CTNNA1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in CTNNA1 are known to be pathogenic (PMID: 32051609, 34425242). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with CTNNA1-related conditions. ClinVar contains an entry for this variant (Variation ID: 944033). For these reasons, this variant has been classified as Pathogenic. |
Ambry Genetics | RCV002379811 | SCV002692831 | uncertain significance | Hereditary cancer-predisposing syndrome | 2022-03-01 | criteria provided, single submitter | clinical testing | The c.1292_1295delTTGA variant, located in coding exon 8 of the CTNNA1 gene, results from a deletion of 4 nucleotides at nucleotide positions 1292 to 1295, causing a translational frameshift with a predicted alternate stop codon (p.I431Rfs*16). This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. The evidence for this gene-disease relationship is limited; therefore, the clinical significance of this alteration is unclear. |
Myriad Genetics, |
RCV003449677 | SCV004186811 | pathogenic | Hereditary diffuse gastric adenocarcinoma | 2023-07-05 | criteria provided, single submitter | clinical testing | This variant is considered pathogenic. This variant creates a frameshift predicted to result in premature protein truncation. |